Shree Ganesh Remedies Q1FY27: consolidated PAT -67% YoY, revenue -42% ahead of Block-7 ramp
PAT -67.47% YoY · revenue -41.79% · margins compressing
₹14.36 Cr
-41.79% YoY
₹1.12 Cr
-67.47% YoY
7.32%
-6.3pp YoY
₹0.87
Shree Ganesh Remedies' consolidated PAT for Q1 FY27 fell 67.5% YoY to ₹1.12 Cr (₹3.45 Cr in Q1 FY26) as revenue from operations dropped 41.8% YoY to ₹14.36 Cr (₹24.67 Cr). Sequentially the decline is sharper still — revenue down 56.7% and PAT down 82.1% versus the seasonally strong Q4 FY26 (₹33.20 Cr revenue, ₹6.27 Cr PAT). Standalone and consolidated numbers are identical this quarter since the wholly-owned US subsidiary, SGRL USA Inc, again contributed NIL revenue and is immaterial to the group, per the auditor's review report. No analyst consensus or brokerage preview for this quarter could be located — the stock is thinly covered — so vsStreet is unknown rather than inferred.
Q1 FY-2027 vs prior quarters
Margins compressed on both counts: net profit margin (PAT/total income) fell to 7.3% from 13.6% YoY and 18.3% QoQ, while operating margin fell to 23.3% from 29.6% YoY and 34.3% QoQ. The compression sits mainly on operating deleverage — cost of materials (₹8.40 Cr) and employee costs (₹2.93 Cr) held roughly flat even as revenue nearly halved sequentially — partly offset by a ₹6.31 Cr finished-goods/WIP inventory build (versus a ₹0.13 Cr build a year ago), which kept reported expenses from falling as much as the topline. Finance costs eased to ₹0.32 Cr from ₹0.94 Cr YoY and ₹0.88 Cr QoQ, providing a small cushion to pre-tax profit.
The stock went into the print at ₹589.95, down 12.6% over the past month of trading.
What the summary numbers don't show
EPS ₹0.87 vs ₹2.68 YoY and ₹4.88 QoQ (not annualised)
Management projects a gradual improvement in momentum through FY27, driven by the new Block-7 capacity commencing production in Q2 and the CRAMS business gaining traction later in the year. While no specific revenue targets were given, they expect to break out of their historical revenue plateau from FY28 onwards, afte
— This quarter: missed
Against management's own May 2026 guidance — a 'gradual improvement in momentum through FY27' driven by the new Block-7 capacity (guided to start production in Q2 FY27, i.e. after this quarter) and CRAMS business traction building 'later in the year' — the Q1 print runs counter to that narrative rather than confirming it: both revenue and profit fell sharply before the capacity addition has even come online, extending the 'consolidation year' softness flagged for FY26 rather than showing the promised inflection. No management press release commentary was available in the record to corroborate or contextualise the numbers. Corporate actions this quarter (a new independent director appointment on Jul 17, an insider-trading window closure on Jun 25, a share-price-movement clarification on Jun 29) are administrative and do not explain the operating decline.
W1
Block-7 capacity commercial production, guided to start Q2 FY27 — next quarter is the first test of management's 'gradual improvement' thesis
W2
CRAMS business traction guided to build 'later in the year' — watch for revenue contribution in H2 FY27
W3
OPM at 23.3% this quarter vs the reiterated 26-28% long-term sustainable EBITDA margin target — track the path back toward that band
Standalone and consolidated are numerically identical this quarter — US subsidiary SGRL USA Inc reported NIL revenue/profit, per the auditor's 'other matters' note. Inventory of finished goods/WIP built up by ₹6.31 Cr (largest single swing among expense lines vs a ₹0.13 Cr YoY build and a ₹3.19 Cr QoQ drawdown), cushioning reported total expenses relative to the revenue drop — worth watching for offtake weakness. No exceptional items disclosed either period.